MedTrace Logo

LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)

NCT05035654 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-12-17

Study results available
· View outcomes & findings →

Summary

This study will assess the safety, tolerability, pharmacokinetics and efficacy of two LYR-220 designs in symptomatic adult chronic rhinosinusitis (CRS) subjects who have had a prior functional endoscopic sinus surgery.

Conditions

  • Chronic Sinusitis
  • Chronic Rhinosinusitis (Diagnosis)

Interventions

DRUG

LYR-220 Design 1 (Part 1 only)

LYR-220 drug matrix (mometasone furoate 7500 µg) Design 1

DRUG

LYR-220 Design 2 (Part 1 and Part 2)

LYR-220 drug matrix (mometasone furoate 7500 µg) Design 2

DRUG

Bilateral sham procedure control (Part 2)

Bilateral sham procedure control

Sponsors & Collaborators

  • Lyra Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-23
Primary Completion
2023-08-30
Completion
2023-08-30
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05035654 on ClinicalTrials.gov